Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $21.59, for a total value of $70,167.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares of the company’s stock, valued at approximately $280,670. This trade represents a 20.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $20.86 on Thursday. The stock has a market capitalization of $1.02 billion, a P/E ratio of -10.98 and a beta of 1.04. The company’s fifty day moving average price is $23.27 and its 200 day moving average price is $24.33. Enliven Therapeutics, Inc. has a 1 year low of $10.90 and a 1 year high of $30.03.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Robert W. Baird boosted their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $38.25.

Institutional Trading of Enliven Therapeutics

Institutional investors have recently modified their holdings of the stock. FMR LLC raised its position in shares of Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Enliven Therapeutics by 43.0% in the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after acquiring an additional 313,019 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Enliven Therapeutics by 9.9% in the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock worth $19,164,000 after acquiring an additional 67,813 shares during the last quarter. State Street Corp increased its position in shares of Enliven Therapeutics by 2.9% during the third quarter. State Street Corp now owns 745,944 shares of the company’s stock worth $19,051,000 after purchasing an additional 21,018 shares in the last quarter. Finally, First Turn Management LLC raised its stake in Enliven Therapeutics by 29.5% in the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after purchasing an additional 121,849 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.